The Dominantly Inherited Alzheimer Disease Network Trials Unit (DIAN-TU) is funded by industry, private and federal support. Through this public/private partnership, the DIAN-TU has launched the first ever trial in dominantly inherited AD to provide advancement of treatments, scientific understanding and improvements in the approach to Alzheimer’s disease drug development.  This public/private partnership continues to facilitate collaborative discussions focused on effective, safe and efficient clinical trial designs and the sharing of information about the latest DIAD research efforts.

DIAN-TU funding and support

Pre-Competitive Collaborations DIAN Expanded Registry DIAN-TU Trial: DIAN-TU-001
First Two Drug Arms
DIAN-TU Trial:
Third Drug Arm
Alzheimer’s Association Alzheimer’s Association Alzheimer’s Association Alzheimer’s Association
DIAN-TU Pharma Consortium DIAN-TU Pharma Consortium Eli Lilly and Company NIH R56AG053267
DIAN-TU Next Generation Prevention Trial
GHR Foundation GHR Foundation F. Hoffman-La Roche Ltd Janssen Pharmaceuticals
Anonymous Foundation Anonymous Foundation Avid Radiopharmaceuticals GE Healthcare
NIH R13AG055232
The DIAD Family Conference
NIH U01AG042791
DIAN Trial: An Opportunity to Prevent Dementia
Eli Lilly and Company NIH R01AG046179
DIAN-TU: Adaptive Prevention Trial
F. Hoffman-La Roche Ltd Accelerating Medicines Partnership
Janssen Pharmaceuticals Cogstate